Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 5, 2009, Pages 545-549

  Uzunhasan, Isil ^a   Yildiz, Ahmet ^b   Coskun, Ugur ^a   Kalyoncuoglu, Muhsin ^a   Baskurt, Murat ^a   Cakar, Mehmet Akif ^a   Kaya, Aysem ^a   Pehlivanoglu, Seckin ^a   Enar, Rasim ^a   Okcun, Baris ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Department of Radiology   (Turkey)

Author keywords

Acute myocardial infarction; Aldosterone; Inflammation; Left ventricular dysfunction

Indexed keywords

ALDOSTERONE; CREATININE; PLACEBO; SODIUM ION; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; BODY MASS; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RHYTHM; HEREDITY; HOSPITAL READMISSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ALDOSTERONE ANTAGONISTS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SPIRONOLACTONE; TURKEY; VENTRICULAR FUNCTION, LEFT;

ANGINA;

EID: 70249112587     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510902802278     Document Type: Article

References (30)

1. American Heart Association. Heart Disease and Stroke Statistics-2004 Update.
2. Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005;111:1106-1113 (Pubitemid 40365470)
3. Katada J, Meguro T, Saito H, Ohashi A, Anzai T, Ogawa S, Yoshikawa T. Persistent cardiac aldosterone synthesis in angi-otensin II type 1A receptor-knockout mice after myocardial infarction. Circulation. 2005;111:2157-2164
4. McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation. 2004;110:3281-3288
5. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthélémy O, Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:2604-2610
6. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109:2213-2220
7. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19:1371-1376
8. Fritsch Neves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep. 2003;5:59-65.
9. Silvestre JS, Heymes C, Oubénaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fi brosis. Circulation. 1999;99:2694-2701
10. Young MJ, Clyne CD, Cole TJ, Funder JW. Cardiac steroido-genesis in the normal and failing heart. J Clin Endocrinol Metab. 2001;86:5121-5126
11. Oestreicher EM, Martinez-Vasquez D, Stone JR, Jonasson L, Roubsanthisuk W, Mukasa K, Adler GK. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation. 2003;108:2517-2523
12. Wehling M, Spes CH, Win N, Janson CP, Schmidt BM, Theisen K, Christ M. Rapid cardiovascular action of aldos-terone in man. J Clin Endocrinol Metab. 1998;83:3517-3522
13. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myo-cardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878
14. Zannad F, Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specifi c emphasis on heart failure. Heart Fail Rev. 2005;10:71-78
15. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76.
16. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone post-acute myocardial infarction heart failure effi cacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321
17. Rodríguez JA, Godoy I, Castro P, Quintana JC, Yovanovich J, spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study. Rev Med Chil. 1997;125:643-652
18. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angi-otensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265
19. Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M, Christ M. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39:351-358
20. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with fi rst anterior acute myocardial infarction. Circulation. 2003;107:2559-2565
21. Greenberg B, Zannad F, Pitt B. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol. 2006;97:34F-40F.
22. Solomon HA. Aldosterone blockade in patients with acute myocardial infarction. Circulation. 2003;108:E173.
23. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol. 2005;93:121-125
24. Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation. 2006;114:2572-2574
25. Pitt B, Fonarow GC, Gheorghiade M, DeedwaniaE, PC, Duprez DA. Improving outcomes in post-acute myocardialR, infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. Am J Cardiol. 2006;97:26F-33F.
26. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033
27. Guideri G. Death in ventricular fi brillation induced by isoproterenol in DOCA-salt pretreated rats preceded by changes in myocardial electrolytes. Life Sci. 1983;33:1353-1362
28. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:1800-1807
29. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332:80-85
30. Borghi C, Ambrosioni E. On behalf of the Survival of Myocar-dial Infarction Long-term Evaluation (SMILE) Study Group, Effects of Zofenopril on Myocardial Ischemia in Post-Myocardial Infarction Patients with Preserved Left Ventricular Function: The Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA Study, Am Heart J. 2007;153:445e7-14